Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Angewandte Chemie (International Ed. in English)|May 4, 2011
Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines?Alexander Straub, Susanne Roehrig, Alexander HillischCurrent Topics in Medicinal Chemistry|February 20, 2010
Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban)Alexander Straub, Susanne Roehrig, Alexander HillischNature Reviews. Drug Discovery|December 18, 2010
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitorElisabeth Perzborn, Susanne Roehrig, Alexander Straub, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|February 9, 2010
Rivaroxaban: a new oral factor Xa inhibitorElisabeth Perzborn, Susanne Roehrig, Alexander Straub, et al.Journal of Medicinal Chemistry|September 16, 2005
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitorSusanne Roehrig, Alexander Straub, Jens Pohlmann, et al.Journal of Thrombosis and Haemostasis : JTH|March 15, 2022
Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIaStefan Heitmeier, Mayken Visser, Adrian Tersteegen, et al.Journal of Medicinal Chemistry|October 27, 2020
Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral PharmacokineticsAlexander Hillisch, Kersten M Gericke, Swen Allerheiligen, et al.Journal of Medicinal Chemistry|September 5, 2023
Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic DisordersSusanne Roehrig, Jens Ackerstaff, Eloísa Jiménez Núñez, et al.Pageof 1